OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis
Sanjay Bandyopadhyay, Saibal Das, Shambo Samrat Samajdar, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 10, pp. 102849-102849
Closed Access | Times Cited: 33
Sanjay Bandyopadhyay, Saibal Das, Shambo Samrat Samajdar, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 10, pp. 102849-102849
Closed Access | Times Cited: 33
Showing 26-50 of 33 citing articles:
Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice
Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu
Current Opinion in Pediatrics (2024) Vol. 36, Iss. 4, pp. 449-455
Closed Access | Times Cited: 2
Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu
Current Opinion in Pediatrics (2024) Vol. 36, Iss. 4, pp. 449-455
Closed Access | Times Cited: 2
Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study
Genki Sato, Hiroshi Uchino, Takahisa Hirose
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 2119-2130
Open Access | Times Cited: 2
Genki Sato, Hiroshi Uchino, Takahisa Hirose
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 2119-2130
Open Access | Times Cited: 2
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
Merve Guney-Coskun, Metin Başaranoğlu
World Journal of Gastroenterology (2024) Vol. 30, Iss. 43, pp. 4682-4688
Closed Access | Times Cited: 2
Merve Guney-Coskun, Metin Başaranoğlu
World Journal of Gastroenterology (2024) Vol. 30, Iss. 43, pp. 4682-4688
Closed Access | Times Cited: 2
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Natália da Silva Lima, Alba Cabaleiro, Eva Nóvoa, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Natália da Silva Lima, Alba Cabaleiro, Eva Nóvoa, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide
Ametov As, И. Е. Шохин, E. A. Rogozhina, et al.
Pharmacy & Pharmacology (2024) Vol. 11, Iss. 4, pp. 324-346
Open Access | Times Cited: 1
Ametov As, И. Е. Шохин, E. A. Rogozhina, et al.
Pharmacy & Pharmacology (2024) Vol. 11, Iss. 4, pp. 324-346
Open Access | Times Cited: 1
Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial
Ahmed Ibrahim Gad, Nevin F. Ibrahim, Noura Almadani, et al.
Diseases (2024) Vol. 12, Iss. 8, pp. 186-186
Open Access | Times Cited: 1
Ahmed Ibrahim Gad, Nevin F. Ibrahim, Noura Almadani, et al.
Diseases (2024) Vol. 12, Iss. 8, pp. 186-186
Open Access | Times Cited: 1
Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD)
Tereza Dusilová, J. Kovár̆, Ivana Laňková, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6100-6100
Open Access | Times Cited: 1
Tereza Dusilová, J. Kovár̆, Ivana Laňková, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6100-6100
Open Access | Times Cited: 1
Bariatric-Metabolic Surgery: A Promising Solution for Non-Alcoholic Steatohepatitis
Arun Kumar
Biology Engineering Medicine and Science Reports (2024) Vol. 10, Iss. 1, pp. 14-16
Open Access
Arun Kumar
Biology Engineering Medicine and Science Reports (2024) Vol. 10, Iss. 1, pp. 14-16
Open Access
An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review
Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, et al.
Hospital Practice (2024)
Closed Access
Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, et al.
Hospital Practice (2024)
Closed Access
